02  ·  Monthly Pulse

Oral Health Pulse

Top signals across five oral health segments, framed for consultant use. Ingredient innovation, whitening regulation, oral microbiome, and the fluoride vs hydroxyapatite debate — updated monthly by Brendan Walsh.

Edition 04  ·  July 2026

July 2026
Global oral care market
$48B
↑ 5.2% CAGR to 2029
Fastest growing segment
Whitening
↑ 8.1% yr — PAP leading premiumisation
Category challenger
nHAp
↑ Hydroxyapatite building RCT evidence
Regulatory watch
Charcoal
↓ ADA/BDA negative evidence active
Top five signals this month Ranked by consultant relevance
01
Therapeutic / preventive Regulatory
Hydroxyapatite gains clinical legitimacy while US regulatory status stays frozen

Hydroxyapatite has moved from niche natural-health positioning into mainstream clinical discussion, with active US trials studying remineralization and dentin hypersensitivity. The FDA still classifies toothpaste as a cosmetic and has not approved hydroxyapatite for anti-caries claims, while EU and Japanese bodies already recognize it.

So what: Brands entering this space need dual-track claims strategies: cosmetic-safe language in the US and efficacy language reserved for markets where regulatory recognition exists.
Tier 1ClinicalTrials.gov — Hydroxyapatite Toothpastes and Enamel Remineralization
Tier 2Ask the Dentist — Is Hydroxyapatite FDA Approved?

Consumer search and social signals also inform velocity rating.

Velocity
02
Cosmetic / whitening
PAP+ is becoming the default peroxide alternative in premium whitening

PAP whitens without releasing free radicals, avoiding the sensitivity and enamel erosion associated with peroxide gels. Multiple direct-to-consumer brands, led by Hismile, have built entire product lines around PAP+, and dental press coverage now frames it as the sensitivity-safe standard, though it underperforms on deep intrinsic stains.

So what: Expect continued share shift toward PAP+ in premium whitening SKUs. Clients should benchmark claims substantiation now, since deep-stain performance gaps are the likely next point of scrutiny.
Tier 2Today's RDH — PAP as an Alternative to Hydrogen Peroxide Whitening

Consumer search and social signals also inform velocity rating.

Velocity
03
Cosmetic / whitening Regulatory
ADA position on charcoal toothpaste remains unchanged despite continued consumer demand

The ADA's position, that no charcoal product has earned the Seal of Acceptance and evidence of safety or efficacy remains insufficient, has not shifted. Cited concerns include enamel abrasion, gum irritation, and absence of fluoride in most formulations.

So what: This is a stable, low-evidence category sustained by consumer trend rather than clinical support. Any client entry needs explicit risk disclosure and no efficacy overreach.
Tier 1ADA Commons — Charcoal Toothpastes Pose Risks with Few Benefits

Consumer search and social signals also inform velocity rating.

Velocity
04
Clinical / restorative
Peri-implantitis is being reframed as a systemic inflammatory condition, not just a local one

New 2026 literature links peri-implant inflammation to elevated systemic markers such as IL-6 and CRP, alongside established risk factors like smoking and diabetes. Active trials are testing antimicrobial photodynamic therapy as a non-surgical alternative to conventional debridement.

So what: As implant volumes grow, demand will build for maintenance protocols and adjunctive therapies marketed on systemic health grounds, not just implant survival.
Tier 1Frontiers — Peri-implantitis as a systemic burden
Tier 1PMC — Peri-implantitis etiology, prevention and management strategies

Consumer search and social signals also inform velocity rating.

Velocity
05
Market / commercial
Oral care market growth is increasingly e-commerce and sustainability driven

Market sizing estimates for 2026 range from roughly $37 billion to $49 billion depending on methodology, with toothpaste holding over half of category revenue. E-commerce now accounts for close to 30 percent of category revenue, up from 18 percent in 2023, and plant-based, biodegradable formulations grew more than 21 percent year over year.

So what: Channel and sustainability shifts are outpacing ingredient innovation as the primary commercial lever. Clients should weight go-to-market and packaging strategy alongside formulation work.
Tier 2Grand View Research — Oral Care Market Size and Share Report
Tier 2Future Market Insights — Oral Care Market Growth and Trends Forecast

Consumer search and social signals also inform velocity rating.

Velocity
Topics to watch
Oral probiotics / synbiotics
Evidence is directionally positive but inconsistent across meta-analyses. Claims substantiation is the key gating issue before a consumer launch is viable.
Peri-implantitis management
No standardized non-surgical treatment protocol exists. Adjunctive antimicrobial photodynamic therapy is still in early trial stages, leaving room for a first-mover implant maintenance product.
Hydroxyapatite (nHAp)
Active US trials are building the evidence base for remineralization and dentin hypersensitivity claims, ahead of any change in FDA classification.
E-commerce and sustainability
E-commerce share and plant-based, biodegradable formulation growth are outpacing ingredient innovation as commercial levers in the category.
Regulatory radar
WatchCharcoal toothpaste — no ADA Seal recognition or safety consensus. Ongoing consumer demand keeps reputational exposure live for any client product in the category.
WatchHydroxyapatite — remains unapproved for anti-caries claims in the US. Claims drafted for EU or Japan markets cannot be reused domestically without regulatory risk.
MonitorPAP+ whitening — adoption is broadening across DTC brands with no adverse safety signal identified to date.
MonitorHydroxyapatite trials — active US clinical trials on remineralization and dentin hypersensitivity are underway, building the evidence base needed for future claims.